Related Experiment Video
Updated: Dec 14, 2025
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target
Hao Xu1, Songshan Chai1, Yihao Wang1
1Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background:
Glioma is a primary malignancy of the central nervous system (CNS). As biomedicine advances, an efficient molecular target is urgently needed for the diagnosis and treatment of glioma. Meanwhile, several studies have demonstrated that glioma development is closely related to immunity. PARP9 is an inactive mono-ADP-ribosyltransferase belonging to the poly-ADP ribosyltransferase (ARTD) family. In this article, we aimed to reveal the relationship between PARP9 and glioma and explore the potential prognostic value and immunotherapeutic targetability of PARP9 in glioma.
Methods:
PARP9 transcript levels were analyzed with TCGA and GEO databases. The clinicopathological information of patients with glioma in the TCGA database and gene expression profiles were analyzed to determine the relationship between the expression of PARP9 and clinicopathologic characteristics. Kaplan-Meier survival analysis, univariate Cox regression analysis, and multivariate Cox regression analysis were used for survival analysis. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were used for bioinformatics analysis. Correlation analysis explored the relationships between PARP9, infiltrating inflammatory immune cells, and immune checkpoint molecules.
Results:
PARP9 is highly expressed in glioma, and high expression of PARP9 is associated with poor prognosis and advanced clinicopathological features. Bioinformatics analysis showed that some immune-related pathways were closely associated with high expression of PARP9. Correlation analysis indicated that PARP9 was closely related to inflammatory and immune responses, high immune cell infiltration, and immune checkpoint molecules.
Conclusions:
PARP9 may serve as an unfavorable prognosis predictor for glioma and a potential immunotherapeutic target.
Insights
High expression of PARP9 in glioma correlates with poor prognosis and advanced disease. PARP9 may be a valuable prognostic marker and a potential target for glioma immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Glioma, a primary central nervous system (CNS) malignancy, requires novel molecular targets for diagnosis and treatment.
- Emerging evidence links glioma development to immune system activity.
- Poly(ADP-ribose) polymerase 9 (PARP9), an inactive enzyme in the ARTD family, is investigated for its role in glioma.
Purpose of the Study:
- To elucidate the relationship between PARP9 and glioma.
- To evaluate the prognostic value of PARP9 in glioma.
- To explore PARP9 as a potential immunotherapeutic target in glioma.
Main Methods:
- Analysis of PARP9 transcript levels using TCGA and GEO databases.
- Correlation of PARP9 expression with clinicopathological characteristics and survival outcomes via Kaplan-Meier and Cox regression analyses.
- Bioinformatic analyses (GSEA, GSVA) and correlation studies with immune cell infiltration and immune checkpoint molecules.
Main Results:
- PARP9 is significantly overexpressed in glioma, correlating with poor prognosis and advanced clinicopathological features.
- High PARP9 expression is associated with immune-related pathways and inflammatory responses.
- PARP9 shows a strong correlation with immune cell infiltration and immune checkpoint molecules.
Conclusions:
- PARP9 serves as a potential unfavorable prognostic predictor for glioma.
- PARP9 represents a promising target for glioma immunotherapy.
